We are live on ! Find out more
CALA

Calithera Biosciences, Inc

Delisted

CALA was delisted on the 1st of February, 2023.

40 hedge funds and large institutions have $27.1M invested in Calithera Biosciences, Inc in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 10

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

9% less funds holding

Funds holding: 4440 (-4)

23% less capital invested

Capital invested by funds: $35.2M → $27.1M (-$8.06M)

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

Holders
40
Holders Change
-4
Holders Change %
-9.09%
% of All Funds
1.07%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
8
Increased
11
Reduced
10
Closed
12
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$10.2M
MMPI
2
Morgenthaler Management Partners IX
California
$7.03M
First Eagle Investment Management
3
First Eagle Investment Management
New York
$1.75M +$1.07M +16,637 +162%
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.36M -$39.6K -615 -3%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$1.18M -$5.29M -82,014 -82%
SM
6
Sabby Management
Florida
$1.05M +$1.05M +16,225 New
BIT
7
BlackRock Institutional Trust
California
$749K -$774 -12 -0.1%
CS
8
Candriam SCA
Luxembourg
$618K
BCM
9
Bridgeway Capital Management
Texas
$513K
Millennium Management
10
Millennium Management
New York
$332K +$16.6K +257 +5%
FSA
11
Franklin Street Advisors
North Carolina
$325K +$50.6K +785 +19%
Renaissance Technologies
12
Renaissance Technologies
New York
$300K +$298K +4,622 New
D.E. Shaw & Co
13
D.E. Shaw & Co
New York
$265K +$143K +2,219 +119%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$214K +$34.6K +536 +19%
DTL
15
Dynamic Technology Lab
Singapore
$187K +$186K +2,878 New
Deutsche Bank
16
Deutsche Bank
Germany
$180K +$112K +1,742 +169%
BFA
17
BlackRock Fund Advisors
California
$115K -$193 -3 -0.2%
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
$88K -$387 -6 -0.4%
FAM
19
Fred Alger Management
New York
$81K +$80.6K +1,250 New
VKH
20
Virtu KCG Holdings
New York
$56K +$55.2K +857 New
Bank of New York Mellon
21
Bank of New York Mellon
New York
$55K -$9.73K -151 -15%
Jacobs Levy Equity Management
22
Jacobs Levy Equity Management
New Jersey
$54K
Northern Trust
23
Northern Trust
Illinois
$54K
WS
24
Wedbush Securities
California
$47K +$9.67K +150 +26%
California Public Employees Retirement System
25
California Public Employees Retirement System
California
$46K

CALA Hedge Fund Activity: Q3 2016 in Review

40 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q3 2016, worth a combined $27.1M — down 23% from $35.2M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of CALA and 8 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 11 added.

The largest buyer was First Eagle Investment Management, adding an estimated $1.07M. The largest seller was Fidelity Investments, cutting an estimated $5.29M.

  • 40 institutional investors held Calithera Biosciences, Inc (CALA) as of Q3 2016, down from 44 in Q2 2016.
  • Funds reported $27.1M of Calithera Biosciences, Inc stock for Q3 2016, down 23% quarter-over-quarter.
  • 8 funds opened new Calithera Biosciences, Inc positions in Q3 2016 and 12 closed out, a net change of -4 holders.
  • The largest Calithera Biosciences, Inc buyer in Q3 2016 was First Eagle Investment Management, an estimated $1.07M added.
  • The largest Calithera Biosciences, Inc seller in Q3 2016 was Fidelity Investments, an estimated $5.29M sold.

Based on aggregated 13F filings for Q3 2016.